PMID- 36544782
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20230113
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation 
      and migration and is associated with dismal prognosis and immunity in lung 
      squamous cell carcinoma.
PG  - 986447
LID - 10.3389/fimmu.2022.986447 [doi]
LID - 986447
AB  - Immunotherapy can improve the survival of patients with advanced lung squamous 
      cell carcinoma (LUSC). T cytotoxic cells are one of the main members of the 
      immune microenvironment. Herein, we aimed to identify the roles of T-cell 
      cytotoxic markers interleukin 18 (IL18) receptor 1 (IL18R1) in the LUSC 
      progression using bioinformatics, clinical tissue specimen, and cell experiment. 
      We assessed the association between the IL18R1 expression and immune infiltration 
      and IL18R1-related competing RNA network. The IL18R1 expression was downregulated 
      in the LUSC tissues. The IL18R1 expression downregulation was associated with 
      diagnosis and short overall survival and disease-specific survival, and it was 
      also an independent risk factor for dismal survival time in LUSC. IL18R1-related 
      nomograms predicted the survival time of patients with LUSC. IL18R1 
      overexpression inhibited the proliferation, migration, and invasion of LUSC 
      cells. The IL18R1 expression was significantly associated with the 
      microenvironment (stromal, immune, and estimate scores), immune cells (such as 
      the T cells, cytotoxic cells, CD8 T cells), and immune cell markers (such as the 
      CD8A, PD-1, and CTLA4) in LUSC. AC091563.1 and RBPMS-AS1 downregulation was 
      positively associated with the IL18R1 expression, negatively associated with the 
      miR-128-3p expression, and associated with short disease-specific survival and 
      progression in LUSC. In conclusion, IL18R1 was significantly downregulated and 
      associated with the prognosis and immune microenvironment. IL18R1 overexpression 
      inhibits the growth and migration of cancer cells in LUSC. Furthermore, 
      AC091563.1 and RBPMS-AS1 might compete with IL18R1 to bind miR-128-3p for 
      participating in LUSC progression. These results showed that IL18R1 is a 
      biomarker for evaluating the prognosis of patients with LUSC.
CI  - Copyright (c) 2022 Guo, Wu, Jiang, Tong, Wan, Xiao, Mei, Liu and Wang.
FAU - Guo, Qiang
AU  - Guo Q
AD  - Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Wu, Chuang-Yan
AU  - Wu CY
AD  - Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Jiang, Ni
AU  - Jiang N
AD  - Department of Obstetrics and Gynecology, Women and Children's Hospital of 
      Chongqing Medical University, Chongqing, China.
FAU - Tong, Song
AU  - Tong S
AD  - Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Wan, Jun-Hao
AU  - Wan JH
AD  - Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Xiao, Xiao-Yue
AU  - Xiao XY
AD  - Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Mei, Pei-Yuan
AU  - Mei PY
AD  - Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
FAU - Liu, Hua-Song
AU  - Liu HS
AD  - Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of 
      Medicine, Shiyan, China.
FAU - Wang, Si-Hua
AU  - Wang SH
AD  - Department of Thoracic Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221205
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CD3 Complex)
RN  - 0 (Interleukin-18 Receptor alpha Subunit)
RN  - 0 (MicroRNAs)
RN  - 0 (IL18R1 protein, human)
SB  - IM
MH  - Humans
MH  - Down-Regulation
MH  - *Carcinoma, Non-Small-Cell Lung
MH  - *Carcinoma, Squamous Cell
MH  - *Antineoplastic Agents
MH  - Prognosis
MH  - CD3 Complex
MH  - Interleukin-18 Receptor alpha Subunit
MH  - *Lung Neoplasms/genetics
MH  - Cell Proliferation
MH  - Lung
MH  - *MicroRNAs/genetics
MH  - Tumor Microenvironment
PMC - PMC9760870
OTO - NOTNLM
OT  - T cytotoxic cells
OT  - immune microenvironment
OT  - interleukin 18 receptor 1
OT  - lung squamous cell carcinoma
OT  - prognosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/23 06:00
MHDA- 2022/12/24 06:00
PMCR- 2022/01/01
CRDT- 2022/12/22 02:22
PHST- 2022/07/05 00:00 [received]
PHST- 2022/11/17 00:00 [accepted]
PHST- 2022/12/22 02:22 [entrez]
PHST- 2022/12/23 06:00 [pubmed]
PHST- 2022/12/24 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.986447 [doi]
PST - epublish
SO  - Front Immunol. 2022 Dec 5;13:986447. doi: 10.3389/fimmu.2022.986447. eCollection 
      2022.